Drug intelligence / Profile preview

CD47 scFv

Development stage
Preclinical
Lead developer
Medical College of Wisconsin
Modality
Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
Administration
Intravenous
01

Overview

CD47 scFv is a single-chain variable fragment (scFv) designed to bind to and block CD47, a cell surface protein that functions as a "do not eat me" signal overexpressed on various malignant tumors, including multiple myeloma. By blocking the interaction between CD47 on tumor cells and SIRP-α on macrophages, it aims to promote tumor phagocytosis by the innate immune system. In research conducted at the Medical College of Wisconsin, this scFv has been utilized both as a standalone agent and as a modular component for generating bispecific antibodies, such as a CD47-CD138 construct. This approach is intended to improve tumor selectivity and reduce off-target toxicities associated with the widespread expression of CD47 on normal tissues, thereby mitigating the "sink effect" and enhancing therapeutic efficacy.

Other names
anti-CD47 scFvanti-CD-47 scFvanti-CD 47 scFvanti-CD47 single chain variable fragmentanti-CD-47 single chain variable fragmentanti-CD 47 single chain variable fragment
02

Targets

CD47 (Cluster of Differentiation 47)

Beyond the preview

Go deeper on CD47 scFv.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on CD47 scFv.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call